

CAT-VHL Exploring the Role of Carbonic Anhydrase IX as Diagnostic and Theranostic Target in Von-Hippel Lindau Disease

NCT07171905

Status	RECRUITING
Phase	Phase 2
Sponsor	IRCCS Ospedale San Raffaele
Enrollment	38 participants

Key Eligibility Criteria

Inclusion (9)

- Voluntarily given informed consent
 - Age ≥18 years old
 - Performance Status ECOG/WHO score 0-2
 - For females of reproductive potential, negative pregnancy test and use of highly effective contraception for 30 days following IMP administration
 - For males of reproductive potential, use of highly effective contraception for 30 days following IMP administration.
- ... and 4 more (see full listing online)

Exclusion (12)

- Performance Status ECOG/WHO score >2
 - Women who are pregnant or breastfeeding or are planning pregnancy during the study
 - Men who are planning fatherhood during the study
 - Exposure to any murine or chimeric antibodies within 5 years prior to the planned IMP administration
 - Exposure to any experimental diagnostic or therapeutic drug within 30 days from the planned IMP administration
- ... and 7 more (see full listing online)

Locations (1 total)

IRCCS Ospedale San Raffaele, Milan, Italia, Italy